A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects With Ulcerative Colitis (UC)
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Upadacitinib (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors AbbVie
- 07 Mar 2017 Planned End Date changed from 20 Aug 2022 to 1 Nov 2022.
- 07 Mar 2017 Planned primary completion date changed from 1 Jan 2027 to 1 Jan 2022.
- 30 Nov 2016 New trial record